Physician profile
Ryan S Owsley
NPI 1659361681
$8,802.84
in general payments reported to CMS, 2019-2025
35 companies · $1,872 in 2025
The $1,872 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $711 · 2021: $772 · 2022: $1,299 · 2023: $1,407 · 2024: $1,672 · 2025: $1,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,768 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,768.27 |
| Education | $183.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,946.44 | 2019-2025 | |
| Janssen Biotech, INC. | $843.26 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $829.38 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $737.35 | 2019-2025 | |
| Lilly USA, LLC | $475.97 | 2019-2025 | Ebglyss, Olumiant |
| Ucb, INC. | $455.76 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $394.04 | 2019-2025 | Nemluvio, Dysport |
| Regeneron Healthcare Solutions, INC. | $345.42 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $211.17 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $209.95 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.15 | 2022-2024 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $123.57 | 2021-2024 | Sotyktu |
| Merz North America, INC. | $113.27 | 2019 | |
| Mimedx Group, INC. | $97.39 | 2024-2025 | |
| Incyte Corporation | $80.30 | 2023-2025 | Opzelura |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $72.68 | 2022 | |
| Vyne Pharmaceuticals INC. | $71.53 | 2021 | |
| Arcutis Biotherapeutics, INC. | $57.54 | 2024 | Zoryve |
| Biofrontera INC. | $56.43 | 2019-2022 | |
| Genzyme Corporation | $54.38 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $48.24 | 2025 | Dupixent |
| Helsinn Therapeutics (U.S.), INC. | $46.05 | 2022-2023 | Valchlor |
| Janssen Scientific Affairs, LLC | $42.35 | 2024 | Tremfya |
| Kerecis Limited | $40.21 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Biowound Solutions, INC. | $37.97 | 2025 | Bio-Connekt |
| Springworks Therapeutics, INC. | $32.88 | 2025 | Gomekli |
| Prugen, INC. Pharmaceuticals | $32.76 | 2019-2020 | |
| Sandoz INC. | $28.48 | 2023 | Hyrimoz |
| Genentech USA, INC. | $25.31 | 2019 | |
| Kyowa Kirin, INC. | $23.32 | 2024 | Poteligeo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.93 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $21.91 | 2023 | Givlaari |
| Menarini Silicon Biosystems, INC. | $17.23 | 2023 | Cellsearch |
| Dermira, INC. | $14.64 | 2020 | |
| Organon LLC | $6.58 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Owsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.